Company Forma Therapeutics Holdings, Inc.

Forma Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for patients with hematologic diseases and cancers. Its pipeline consists of six product candidates. Its product candidates include etavopivat, FT-7051, Olutasidenib- Acute Myeloid Leukemia IDH1m inhibitor, and Olutasidenib Glioma IDH1m inhibitor. Its lead product candidate, etavopivat, is an oral, once-daily, potentially disease-modifying therapy for the treatment of sickle cell disease (SCD), and other hemoglobinopathies. Its product candidate, FT-7051, is an inhibitor of CREB-binding protein/E1A binding protein p300, or CBP/p300 for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Olutasidenib is an oral, selective small molecule investigational agent designed to selectively bind to and inhibit mutated IDH1 enzymes.

Number of employees: 189